Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax, Inc. (NASDAQ:NVAX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.
多位內部人士在過去一年裏賣出股份後，諾瓦瓦克斯醫藥股份股東們可能有理由擔心。評估內部人士交易時，了解內部人士是否購買的信息通常比了解他們是否賣出更有益，因爲後者可以有多種解讀。但是，如果多個內部人士在賣出，股東應該進行更多調查。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
雖然在長期投資方面內部交易並非最重要的事情，但完全忽略內部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At Novavax
諾瓦瓦克斯醫藥內部交易的過去12個月
In the last twelve months, the biggest single sale by an insider was when the President of Research & Development, Filip Dubovsky, sold US$384k worth of shares at a price of US$13.90 per share. So what is clear is that an insider saw fit to sell at around the current price of US$13.11. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
在過去的12個月中，研發總裁Filip Dubovsky賣出了價值384,000美元的股票，每股價格爲13.9美元，是所有內部人員最大的單筆賣出。因此，明顯有內部人士認爲出售價格在當前價位13.11美元左右比較合適。雖然內部人士的賣出行爲是負面的，但對我們來說，如果股票價格更低時賣出，就更加負面。我們注意到此次交易發生在當前價格附近，因此不太引起關注，但也不算好跡象。
Over the last year we saw more insider selling of Novavax shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去的一年中，我們看到更多內部人員賣出諾瓦瓦克斯醫藥的股票，而不是買入。您可以在下面看到過去12個月內部交易（由公司和個人）的視覺描述。如果您想知道是誰以多少價格和何時賣出，請單擊下面的圖表！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人，可以免費查看最新內部交易股票的小盤公司名單，這可能正是您要找的機會。
Insiders At Novavax Have Sold Stock Recently
諾瓦瓦克斯醫藥的內部人員最近出售了股票
There was substantially more insider selling, than buying, of Novavax shares over the last three months. In total, insiders sold US$593k worth of shares in that time. On the flip side, insider Himanshu Shah spent US$34k on purchasing shares (as mentioned above) . The share price has moved a bit recently, but it's hard to argue that the selling is a positive.
過去三個月內，諾瓦瓦克斯醫藥的內部人士賣出的股票遠高於購買，總共在該時間段內賣出了價值593,000美元的股票。另一方面，內部人員Himanshu Shah購買了價值34,000美元的股票（如上所述）。股價最近有些波動，但很難認爲賣出是一種積極的信號。
Insider Ownership
內部人員持股情況
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.3% of Novavax shares, worth about US$6.8m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
查看公司內部股權總額可以幫助您了解股東與普通股東是否有很好的對齊。持有高比例股權的內部人員通常會更加關注股東利益。根據我們的數據，內部人員擁有諾瓦瓦克斯醫藥0.3%的股權，價值約6.8百萬美元。雖然比沒有強，但我們對這些持股不太滿意。
What Might The Insider Transactions At Novavax Tell Us?
諾瓦瓦克斯醫藥的內部交易可能意味着什麼？
The stark truth for Novavax is that there has been more insider selling than insider buying in the last three months. Zooming out, the longer term picture doesn't give us much comfort. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Novavax. To that end, you should learn about the 4 warning signs we've spotted with Novavax (including 3 which are concerning).
對於諾瓦瓦克斯醫藥來說，殘酷的事實是，在過去的三個月中，內部人員賣出的股票比買入的多。回歸長期，情況也不太讓我們感到舒適。考慮到大多數公司擁有更高比例的內部持股，我們有些警惕。因此，我們只會在非常謹慎地考慮之後購買。除了了解正在進行的內部交易之外，還要確定諾瓦瓦克斯醫藥面臨的風險。爲此，您應該了解我們發現的4個警告信號（包括3個令人擔憂的信號）。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然，您可能會在其他地方找到一項出色的投資。因此，請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。